Mark Turmaine
Overview
Explore the profile of Mark Turmaine including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1888
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fazal S, Mutschler C, Chen C, Turmaine M, Chen C, Hsueh Y, et al.
Front Cell Neurosci
. 2023 Apr;
17:1158388.
PMID: 37091921
Since SARM1 mutations have been identified in human neurological disease, SARM1 inhibition has become an attractive therapeutic strategy to preserve axons in a variety of disorders of the peripheral (PNS)...
2.
Piatkowska A, Adhikari K, Moverley A, Turmaine M, Glazier J, Plachta N, et al.
J Anat
. 2022 Nov;
242(3):417-435.
PMID: 36423208
Somites are transient structures derived from the pre-somitic mesoderm (PSM), involving mesenchyme-to-epithelial transition (MET) where the cells change their shape and polarize. Using Scanning electron microscopy (SEM), immunocytochemistry and confocal...
3.
Rezaei A, Li Y, Turmaine M, Bertazzo S, Howard C, Arnett T, et al.
Sci Rep
. 2022 Aug;
12(1):13944.
PMID: 35977987
Diabetic patients have an increased risk of fracture and an increased occurrence of impaired fracture healing. Diabetic and hyperglycaemic conditions have been shown to impair the cellular response to hypoxia,...
4.
Garriboli M, Deguchi K, Totonelli G, Georgiades F, Urbani L, Ghionzoli M, et al.
Pediatr Surg Int
. 2022 Mar;
38(5):665-677.
PMID: 35316841
Purpose: Enterocystoplasty is adopted for patients requiring bladder augmentation, but significant long-term complications highlight need for alternatives. We established a protocol for creating a natural-derived bladder extracellular matrix (BEM) for...
5.
Savvidis S, Gerli M, Pellegrini M, Massimi L, Hagen C, Endrizzi M, et al.
Acta Biomater
. 2022 Jan;
141:290-299.
PMID: 35051630
Tissue engineering (TE) aims to generate bioengineered constructs which can offer a surgical treatment for many conditions involving tissue or organ loss. Construct generation must be guided by suitable assessment...
6.
Briston T, Stephen J, Thomas L, Esposito C, Chung Y, Syafruddin S, et al.
Front Oncol
. 2021 Oct;
11:740273.
PMID: 34631576
[This corrects the article DOI: 10.3389/fonc.2018.00388.].
7.
Alic I, Goh P, Murray A, Portelius E, Gkanatsiou E, Gough G, et al.
Mol Psychiatry
. 2021 Jul;
26(10):5789.
PMID: 34272490
No abstract available.
8.
Wagstaff L, Gomez-Sanchez J, Fazal S, Otto G, Kilpatrick A, Michael K, et al.
Elife
. 2021 Jan;
10.
PMID: 33475496
After nerve injury, myelin and Remak Schwann cells reprogram to repair cells specialized for regeneration. Normally providing strong regenerative support, these cells fail in aging animals, and during chronic denervation...
9.
Alic I, Goh P, Murray A, Portelius E, Gkanatsiou E, Gough G, et al.
Mol Psychiatry
. 2020 Jul;
26(10):5766-5788.
PMID: 32647257
A population of more than six million people worldwide at high risk of Alzheimer's disease (AD) are those with Down Syndrome (DS, caused by trisomy 21 (T21)), 70% of whom...
10.
Aguti S, Bolduc V, Ala P, Turmaine M, Bonnemann C, Muntoni F, et al.
Mol Ther Nucleic Acids
. 2020 Jun;
21:205-216.
PMID: 32585628
Collagen VI-related congenital muscular dystrophies (COL6-CMDs) are the second most common form of congenital muscular dystrophy. Currently, there is no effective treatment available. COL6-CMDs are caused by recessive or dominant...